The Survival read-out on the Summit Therapeutics (SMMT)’ HARMONi-2 study is one of the most anticipated biotech datapoints this year, and Truist tells investors in a research note that its biostatistics expert consultation gives the firm confidence that this study could beat expectations, and may even show statistical significance. The firm believes that the consensus “home-run scenario” will drive up Summit shares materially if it plays out. Truist has a Buy rating and $35 price target on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Optimistic Buy Rating for Summit Therapeutics Driven by Promising HARMONi-2 Trial and Favorable Regulatory Pathway in China
- Promising Potential of Ivonescimab in Oncology: A Buy Recommendation for Summit Therapeutics
- Moleculin, CNS, Global-e, Tenet, Summit: Trending by Analysts
- Summit Therapeutics upgraded to Buy from Neutral at Citi
- FedEx downgraded, Adobe upgraded: Wall Street’s top analyst calls